Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: ViraCide Softgels: ViraCide softgels: 3 soft gels, two times every day after breakfast and dinner for 14 days+ SOC Therapy
Control Intervention1: Placebo softgels: Placebo softgels: 3 s
Sponsors
Natural Supplemets LLC
Eligibility
Inclusion criteria
Inclusion criteria: 1. 50 years or older 2. Both male and female subjects will be included 3. Positive oropharyngeal/nasal swab RT-PCR for Sars-Co-V2. Diagnosed not more than 2 days ago (diagnosis 4. Either asymptomatic or have mild symptoms. Onset of symptoms within no more than 4 days If symptomatic, symptoms are mild (cough, weakness, sore throat, low grade fever 38.50С, respiratory rate should not be more than 22 / min, resting SpO2 >95%, normal highly sensitive C-reactive protein (HS-CRP) ( 5. Chronic stable medical conditions: diabetes mellitus, or hypertension, or chronic heart disease. Under treatment and controlled by medication 6. Signed informed consent/or consent given through text message, WhatsApp or e-mail. 7. Ability to understand the requirements of the Research Protocol and follow the research procedures. 8. Subject should be willing to be managed in isolation wards 9. Negative pregnancy test (for female participants) 10. Adequate contraception for study duration
Exclusion criteria
Exclusion criteria: 1. Less than 50 years 2. With severe COVID-19 symptoms requiring immediate hospitalization 3. Investigator considers the subject unsuitable for ViraCide 4. History of symptoms of more than 4 days 5. COVID-19 diagnosed >2 days ago using oropharyngeal/nasal swab RT-PCR for Sars-Co-V2 6. History of cardiopulmonary resuscitation 7. Subjects having history of organ failure or conditions requiring ICU monitoring and treatment, such as severe liver disease, severe renal dysfunction, upper gastrointestinal hemorrhage, disseminated intravascular coagulation or any other condition that in the PIâ??s opinion makes the subject unfit to participate 8. Respiratory failure, ARDS or need of mechanical ventilation 9. History of acute exacerbation of comorbidity like heart failure, diabetic kedoacidosis, myocardial infection, major cardiac rhythm disorder or any other condition that in the PIâ??s opinion makes the subject unfit to participate 10. History of or current hepatic failure or severely compromised liver function, or renal failure or having chronic kidney disease or acute renal failure 11. History of or currently receiving treatment for an endocrine disorder like hypothyroidism, hyperthyroidism that is likely to affect the basal heart rate. 12. History of or currently under treatment for asthma [exception: patients with history of asthma, not on medications/inhalers/nebulizers for at least 6 months before study start), COPD, bronchiectasis, asbestosis and other such chronic lung conditions that can compromise SpO2 and RR. 13. HIV, HBsAg, HCV positive 14. Any condition causing immunodeficiency 15. Systemic connective tissue disease or any autoimmune disease that is likely to affect HS-CRP levels 16. History of epilepsy/epileptic fit/convulsions in last 6 months or currently on treatment for it 17. History of or currently having malignancy and being treated for it. (exception: histologically confirmed and cured carcinoma in situ) 18. Hypersensitivity reaction to Study drug/placebo 19. Any psychiatric issue for which the subject is currently undergoing treatment 20. Any history of drug/alcohol dependence within 30 days of screening or current drug/alcohol dependence 21. Inability to understand the requirements of the Research Protocol and follow the research procedures. 22. Pregnant or lactating; 23. Not willing to use adequate contraception during study duration 24. Participation in any other clinical study less than 3 months before the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To evaluate the efficacy of â??ViraCideâ?? in the management of mild COVID-19 diseaseTimepoint: Baseline, day 7 and day 15 | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the safety of â??ViraCideâ?? in the management of mild COVID-19 diseaseTimepoint: Baseline, day 7, day 15 , day 28 | — |
Countries
India
Contacts
Public ContactMr Sohal Pendse
ProRelix Research
Outcome results
None listed